Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Financing Activities (2019 - 2025)

IDEAYA Biosciences' Cash from Financing Activities history spans 7 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 22.63% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $29.8 million, down 95.6%, while the annual FY2025 figure was $29.8 million, 95.6% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $2.1 million at IDEAYA Biosciences, up from $301000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $349.1 million in Q1 2024 and bottomed at $301000.0 in Q3 2025.
  • The 5-year median for Cash from Financing Activities is $21.1 million (2021), against an average of $65.6 million.
  • The largest annual shift saw Cash from Financing Activities surged 123441.18% in 2021 before it plummeted 99.89% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $688000.0 in 2021, then crashed by 52.91% to $324000.0 in 2022, then surged by 43385.8% to $140.9 million in 2023, then plummeted by 98.05% to $2.8 million in 2024, then decreased by 22.63% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Cash from Financing Activities are $2.1 million (Q4 2025), $301000.0 (Q3 2025), and $1.2 million (Q2 2025).